Louis Muglia, M.D., Ph.D., president and CEO of the Burroughs Wellcome Fund and medical geneticist and pediatrician known for his groundbreaking research on preterm birth and prenatal testing, delivered "The Time to Be Born" at the Heersink Grand Rounds on Jan. 30.. His talk explored the complex mechanisms that determine birth timing and the genetic factors involved.

The UAB campus is rapidly being reimagined through numerous new construction and building renovation projects. These include projects that directly support the goals of UAB’s Forging Ahead strategic plan and Research Strategic Initiative: Growth with Purpose, which set a goal of increasing research expenditures to $1 billion, from $774.5 million in fiscal year 2023. Several projects also advance the Heersink School of Medicine’s strategic goals across its mission pillars in clinical care, medical education, and biomedical research. 

Heersink School of Medicine awarded nine staff members as the 2024 Dean’s Excellence Awards for Staff winners. Individuals selected for this honor showcased outstanding accomplishments beyond their daily duties and contributed considerably to Heersink’s core mission areas – education, clinical care, and basic, translational, and clinical research.

Cassandra Newsom, Psy.D., director of the Translational Research Core in Autism and Neurodevelopment of Civitan International Research Center, has completed participation in Phase 2 Clinical Trials of a new drug, NNZ-2591, that shows promising results for a devastating neurodevelopmental disorder called Pitt-Hopkins Syndrome (PTHS).

Orlando Gutiérrez, M.D., will be appointed senior associate dean for Clinical and Translational Research in the UAB Marnix E. Heersink School of Medicine and director and contact principal investigator of the UAB Center for Clinical and Translational Science. In this role, Gutiérrez will also serve as the associate vice president of Medicine and Biomedical Research for UAB. In turn, Robert Kimberly, M.D., will transition into the newly created role of senior associate dean for Strategic Initiatives in the Heersink School of Medicine. Both appointments are effective April 1, 2024.

On Thursday, May 18, UAB celebrated Clinical Trials Day. Since 2020, UAB has averaged nearly 300 new clinical trials annually.

As the Heersink School of Medicine grows, the leadership has defined four new research focus areas to grow over the next five to seven years. This part explores the second focus area, Health Equity.